CD34 and neoplasm: Mozhdeh Foroozan and colleagues demonstrated that an elevated expression of the endothelial cell marker CD34 in prostate cancer (PCa) correlates with increased tumor aggressiveness, establishing CD34 as a valuable prognostic indicator [108].